Lupin will hold a meeting of the Board of Directors of the Company on 28 January 2021.

Powered by Capital Market - Live News

Lupin Ltd gained for a third straight session today. The stock is quoting at Rs 1069.45, up 2.95% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 14437.1. The Sensex is at 49119.8, up 0.69%. Lupin Ltd has gained around 13.6% in last one month.

Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has gained around 7.32% in last one month and is currently quoting at 13271.55, up 0.75% on the day. The volume in the stock stood at 30.3 lakh shares today, compared to the daily average of 37.53 lakh shares in last one month.

The benchmark January futures contract for the stock is quoting at Rs 1072.75, up 2.8% on the day. Lupin Ltd is up 42.86% in last one year as compared to a 17.09% jump in NIFTY and a 65.52% jump in the Nifty Pharma index.

The PE of the stock is 39.39 based on TTM earnings ending September 20.

Powered by Capital Market - Live News

Lupin has received tentative approval for its Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 rng/1000 mg, from the United States Food and Drug Administration, to market a generic equivalent of Synjardy6 XR Tablets, 5 mg/1000 mg, 10 mg/1000 mg, 12.5 mg/1000 mg, and 25 mg/1000 mg, of Boehringer Ingelheim Pharmaceuticals, Inc. The product will be manufactured at Lupin's Nagpur facility in India.

Empagliflozin and Metformin Hydrochloride Extended-Release (ER) Tablets, 5 mg/1000 mg, 10 mg/1000 mg,12.5 mg/1000 mg, and 25 mg/1000 mg, are indicated as an adjunct to diet and exercise, to improve glycemiccontrol in adults with type 2 diabetes mellitus when treatment with both empaglifiozin and metforminhydrochloride is appropriate.

Empagliflozin and Metformin Hydrochloride ER Tablets (RLD: SynjardytXR) had estimated annual sales ofUSD 357 million in the U.S. (IQVIA MAT November 2020).

Powered by Capital Market - Live News

Lupin has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent ofBactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.

Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for thetreatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, andintestinal infections), and certain type of pneumonia (pneumocystis-type).

Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales ofapproximately USD 19 million in the U.S. (IQVIA MAT September 2020).

Powered by Capital Market - Live News